Rationale for Development of New Oral Anticoagulants

Title:Rationale for Development of New Oral Anticoagulants

Volume: 15 Issue: 2

Author(s): Muharrem Akin, Julian Widder, Ibrahim Akin, Michael Brehm and Andreas Schäfer

Affiliation:

Keywords: Coumadin, novel oral anticoagulation, thrombembolism, warfarin.

Abstract: The development of new or direct oral anticoagulants was triggered by the disadvantages of classic oral anticoagulation, which was isolated in Link’s laboratory in 1940. Some of these limitations are the individual variation in response to these drugs, drug interaction and the need for regular laboratory monitoring. With increasing comorbidity and life expectancy in populations these limitations led to interruption of treatment or even underuse of treatment in light of potential side effects. With the introduction of novel oral anticoagulants some of these drawbacks are targeted whereas even these drugs also have some limitations and should be given with cautions and not to all patients having an indication for anticoagulation.

Cite this article as:

Akin Muharrem, Widder Julian, Akin Ibrahim, Brehm Michael and Schäfer Andreas, Rationale for Development of New Oral Anticoagulants, Cardiovascular & Hematological Disorders-Drug Targets 2015; 15 (2) . https://dx.doi.org/10.2174/1871529X1502151209110044